ZA201807903B - Methods of treating circadian rhythm sleep disorders - Google Patents

Methods of treating circadian rhythm sleep disorders

Info

Publication number
ZA201807903B
ZA201807903B ZA2018/07903A ZA201807903A ZA201807903B ZA 201807903 B ZA201807903 B ZA 201807903B ZA 2018/07903 A ZA2018/07903 A ZA 2018/07903A ZA 201807903 A ZA201807903 A ZA 201807903A ZA 201807903 B ZA201807903 B ZA 201807903B
Authority
ZA
South Africa
Prior art keywords
methods
sleep disorders
circadian rhythm
rhythm sleep
treating circadian
Prior art date
Application number
ZA2018/07903A
Other languages
English (en)
Inventor
T Beuckmann Carsten
Moline Margaret
Satlin Andrew
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of ZA201807903B publication Critical patent/ZA201807903B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2018/07903A 2016-05-12 2018-11-22 Methods of treating circadian rhythm sleep disorders ZA201807903B (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662335611P 2016-05-12 2016-05-12
US201662335599P 2016-05-12 2016-05-12
US201662413976P 2016-10-27 2016-10-27
US201662414599P 2016-10-28 2016-10-28
US201662414606P 2016-10-28 2016-10-28
PCT/US2017/032228 WO2017197160A1 (en) 2016-05-12 2017-05-11 Methods of treating circadian rhythm sleep disorders

Publications (1)

Publication Number Publication Date
ZA201807903B true ZA201807903B (en) 2021-04-28

Family

ID=58745465

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/07903A ZA201807903B (en) 2016-05-12 2018-11-22 Methods of treating circadian rhythm sleep disorders

Country Status (16)

Country Link
US (2) US11096941B2 (enExample)
EP (2) EP3454859B1 (enExample)
JP (2) JP6888026B2 (enExample)
KR (2) KR20230043227A (enExample)
CN (1) CN109640998A (enExample)
AU (3) AU2017264871B2 (enExample)
CA (1) CA3022068A1 (enExample)
ES (1) ES2904625T3 (enExample)
IL (2) IL291791B2 (enExample)
MX (1) MX379318B (enExample)
MY (1) MY199382A (enExample)
RU (1) RU2763493C2 (enExample)
SG (1) SG11201809527UA (enExample)
TW (1) TWI795359B (enExample)
WO (1) WO2017197160A1 (enExample)
ZA (1) ZA201807903B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2763493C2 (ru) * 2016-05-12 2021-12-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способы лечения расстройств циркадного ритма сна
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
CA3144067A1 (en) * 2019-06-26 2020-12-30 Eisai R&D Management Co., Ltd. Lemborexant for treating sleep issues
CA3151634A1 (en) * 2019-09-13 2021-03-18 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating insomnia
EP4073058A1 (en) * 2019-12-11 2022-10-19 Teva Czech Industries s.r.o. Solid state form of lemborexant
MX2022008260A (es) * 2020-01-16 2022-08-04 Eisai R&D Man Co Ltd Sustancia farmacologica de lemborexant y composicion medicinal que la comprende.
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
EP4376954A1 (en) * 2021-07-26 2024-06-05 Eisai R&D Management Co., Ltd. Lemborexant for use in methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
CN116421605B (zh) * 2022-01-04 2024-08-02 中国科学院脑科学与智能技术卓越创新中心 Isx-9在治疗衰老相关的昼夜节律幅度下降和睡眠障碍方面的应用
CA3266968A1 (en) 2022-09-23 2024-03-28 Eisai R&D Management Co., Ltd. Methods of reducing neurodegeneration associated with neurodegenerative diseases
CN121646412A (zh) 2023-08-08 2026-03-10 株式会社明治 昼夜节律的调整

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556753C (en) * 2004-02-20 2014-11-25 Lifescape Biosciences Incorporated Compositions and methods for sleep regulation
WO2008026149A1 (en) * 2006-08-28 2008-03-06 Actelion Pharmaceuticals Ltd 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists
MY160969A (en) 2010-09-22 2017-03-31 Eisai R&D Man Co Ltd Cyclopropane compounds
RU2014136339A (ru) * 2012-02-07 2016-03-27 Иолас Терапьютикс, Инк. Замещенные пролины/пиперидины как антагонисты орексиновых рецепторов
MX376164B (es) * 2014-10-23 2025-03-07 Eisai R&D Man Co Ltd Composiciones y metodos para tratar el insomnio.
RU2763493C2 (ru) * 2016-05-12 2021-12-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способы лечения расстройств циркадного ритма сна

Also Published As

Publication number Publication date
EP3454859A1 (en) 2019-03-20
KR20190013820A (ko) 2019-02-11
MX2018013663A (es) 2019-07-18
CA3022068A1 (en) 2017-11-16
EP3454859B1 (en) 2021-12-01
TWI795359B (zh) 2023-03-11
US20210353625A1 (en) 2021-11-18
MY199382A (en) 2023-10-25
US20200179382A1 (en) 2020-06-11
MX379318B (es) 2025-03-10
KR20230043227A (ko) 2023-03-30
TW201740952A (zh) 2017-12-01
IL262803A (en) 2018-12-31
IL291791A (en) 2022-06-01
NZ748555A (en) 2025-06-27
RU2018143809A3 (enExample) 2020-09-17
RU2018143809A (ru) 2020-06-15
JP2021120410A (ja) 2021-08-19
AU2017264871B2 (en) 2023-03-16
IL262803B (en) 2022-05-01
KR102511855B1 (ko) 2023-03-20
AU2017264871A1 (en) 2018-11-15
IL291791B1 (en) 2025-05-01
WO2017197160A1 (en) 2017-11-16
ES2904625T3 (es) 2022-04-05
US11096941B2 (en) 2021-08-24
IL291791B2 (en) 2025-09-01
BR112018073037A2 (pt) 2019-02-26
JP7150096B2 (ja) 2022-10-07
SG11201809527UA (en) 2018-11-29
EP4056180A1 (en) 2022-09-14
JP2019518732A (ja) 2019-07-04
AU2025205336A1 (en) 2025-07-31
JP6888026B2 (ja) 2021-06-16
CN109640998A (zh) 2019-04-16
AU2023203418A1 (en) 2023-06-29
RU2763493C2 (ru) 2021-12-29

Similar Documents

Publication Publication Date Title
ZA201807903B (en) Methods of treating circadian rhythm sleep disorders
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
IL263783A (en) Quinazoline and indole compounds for the treatment of medical disorders
IL269302A (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
IL253244A0 (en) Methods for treating retinal diseases
PT3212233T (pt) Terapia combinada para o tratamento de doenças
SMT201900176T1 (it) Terapia con mrna per il trattamento di malattie oculari
ZA201901055B (en) Treatment and prevention of sleep disorders
GB201405232D0 (en) Apparatus and methods for the treatment of ocular disorders
IL269082A (en) Methods for treating lysosomal disorders
ZA201702214B (en) Methods of using interleukin-10 for treating diseases and disorders
IL267229A (en) Methods of treating ocular disorders
IL275654A (en) Methods of treating CASTOR-related disorders
ZA201903873B (en) Methods of treating cochlear synaptopathy
ZA201902091B (en) Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
GB201408387D0 (en) Treatment of respiratory disorders
GB201607388D0 (en) Treatment of impulsivity-related disorders
IL265971B (en) Therapeutic materials and methods for their production
ZA202002910B (en) Treatment of skin disorders
IL267044A (en) Photodynamic therapeutic compounds and photodynamic treatment methods
EP3151824A4 (en) Methods of treating neurodevelopmental diseases and disorders
GB201520600D0 (en) Treatment of central nervous tumours
IL248385A0 (en) Treatment of circadian rhythm disorder
EP3558288A4 (en) L-PAG DERIVATIVES FOR THE TREATMENT OF RESPIRATORY SLEEP DISORDERS (SDB)
GB201604359D0 (en) Treatment of tissue disorders